CareLit · DOI-Nachweis · Pneumologie
Effects of tezacaftor/ivacaftor (TEZ/IVA) treatment in patients heterozygous for F508del-CFTR and a residual function mutation: patient-reported outcomes in a Phase 3, randomised, controlled trial (EXPAND)
DOI 10.1055/s-0039-1678161
Bibliografische Angaben
Nachweis in CareLit
Autor:innenR Fischer, AA Rizio, B Loop, J Lekstrom-Himes, X You, M Kosinski, R Rendas-Baum, J Davies, SM Rowe, Y Yang
ZeitschriftPneumologie
AusgabeS 01 S 01/2019
Jahrgang / SeitenJg. 73
Kernaussage aus der Literatur
Abstract-Vorschau
Effects of tezacaftor/ivacaftor (TEZ/IVA) treatment in patients heterozygous for F508del-CFTR and a residual function mutation: patient-reported outcomes in a Phase 3, randomised, controlled trial (EXPAND)
Zitieren
Zitierempfehlung
R Fischer, AA Rizio, B Loop, J Lekstrom-Himes, X You, M Kosinski, R Rendas-Baum, J Davies, SM Rowe, Y Yang (2019) Effects of tezacaftor/ivacaftor (TEZ/IVA) treatment in patients heterozygous for F508del-CFTR and a residual function mutation: patient-reported outcomes in a Phase 3, randomised, controlled trial (EXPAND). Pneumologie, 73 (S 01 S 01). https://doi.org/10.1055/s-0039-1678161
Mit CareLit weiterarbeiten